The variation in reported prevalence of growth hormone deficiency (GHD) post subarachnoid haemorrhage (SAH) is mainly due to methodological heterogeneity. We report on the prevalence of GHD in a large cohort of patients following SAH, when dynamic and confirmatory pituitary hormone testing methods are systematically employed.
In this cross-sectional study, pituitary function was assessed in 100 patients following SAH. Baseline pituitary hormonal profile measurement and glucagon stimulation testing (GST) was carried out in all patients. Isolated GHD was confirmed with an Arginine stimulation test and ACTH deficiency was confirmed with a short synacthen test.
The prevalence of hypopituitarism in our cohort was 19% and the prevalence of GHD was 14%. There was no association between GHD and the clinical or radiological severity of SAH at presentation, treatment modality, age, or occurrence of vasospasm. There were statistically significant differences in terms of Glasgow Outcome Scale (GOS; p = 0.03) between patients diagnosed with GHD and those without. Significant inverse correlations between GH peak on GST with body mass index (BMI) and waist hip ratio (WHR) was also noted (p < 0.0001 and p < 0.0001 respectively).
Using the current testing protocol, the prevalence of GHD detected in our cohort was 14%. It is unclear if the BMI and WHR difference observed is truly due to GHD or confounded by the endocrine tests used in this protocol. There is possibly an association between the development of GHD and worse GOS score. Routine endocrine screening of all SAH survivors with dynamic tests is time consuming and may subject many patients to unnecessary side-effects. Furthermore the degree of clinical benefit derived from growth hormone replacement in this patient group, remains unclear. Increased understanding of the most appropriate testing methodology in this patient group and more importantly which SAH survivors would derive most benefit from GHD screening is required.
Tanriverdi F, Dagli AT, Karaca Z, Unluhizarci K, Selcuklu A, Casanueva FF et al (2007) High risk of pituitary dysfunction due to aneurysmal subarachnoid haemorrhage: a prospective investigation of anterior pituitary function in the acute phase and 12 months after the event. Clin Endocrinol 67(6):931–937 CrossRef
Aimaretti G, Ambrosio MR, Di Somma C, Fusco A, Cannavo S, Gasperi M et al (2004) Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol 61(3):320–326 CrossRef
Hannon MJ, Behan LA, O’Brien MM, Tormey W, Javadpour M, Sherlock M et al (2014) Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage. Clin Endocrinol 82:115–121 CrossRef
Klose M, Brennum J, Poulsgaard L, Kosteljanetz M, Wagner A, Feldt-Rasmussen U (2010) Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. Clin Endocrinol 73(1):95–101
Drake CG (1988) Report of World-Federation-of-Neurological-Surgeons Committee on a Universal subarachnoid hemorrhage Grading Scale. J Neurosurg 68(6):985–986
Jennett B, Bond M (1975) Assessment of outcome after severe brain-damage - practical scale. The Lancet 1(7905):480–484 CrossRef
NICE. Quality of life. Assessment of GH deficiency in adults. https://www.nice.org.uk/guidance/ta64/documents/questionnaire-quality-of-life-assessment-of-deficiency-in-adults2.
(NICE) NIoHaCE (2003) Human growth hormone (somatropin) in adults with growth hormone deficiency. https://www.nice.org.uk/guidance/ta64.
Svensson J, Johannsson G, Bengtsson BA (1997) Insulin-like growth factor-I in growth hormone-deficient adults: Relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol 46(5):579–586 CrossRef
Toogood AA, Jones J, O’Neill PA, Thorner MO, Shalet SM (1998) The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol 48(5):569–576 CrossRef
Lissett CA, Thompson EGE, Rahlm A, Brennan BMD, Shalet SM (1999) How many tests are required to diagnose growth hormone (GH) deficiency in adults? Clin Endocrinol 51(5):551–557 CrossRef
Hoffman AR, Kuntze JE, Baptista J, Baum HBA, Baumann GP, Biller BMK et al (2004) Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89(5):2048–2056 CrossRefPubMed
Dichtel LE, Yuen KCJ, Bredella MA, Gerweck AV, Russell BM, Riccio AD et al (2014) Overweight/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. J Clin Endocrinol Metab 99(12):4712–4719 CrossRefPubMedPubMedCentral
Vahl N, Jorgensen JOL, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS (1997) Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol-Endocrinol Metab 272(6):E1108–E1116
Ho KKY, Works GHDC (2007) Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157(6):695–700 CrossRefPubMed
- The prevalence of growth hormone deficiency in survivors of subarachnoid haemorrhage: results from a large single centre study
Calvin J. Heal
- Springer US
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II